Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

591
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
591
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

438
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
438

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mark Hallet (1943-2025).

Neurology·2026
Same author

Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection-a single-center retrospective observational study.

Therapeutic advances in infectious disease·2026
Same author

The "Hallett Sign" of Functional Jerky Movement Disorder.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Using an MR-Compatible Cannula: 48 Weeks of Follow-Up.

Journal of inherited metabolic disease·2026
Same author

Show and Tell.

Journal of general internal medicine·2026
Same author

Commentary on "From Gloom to Bloom".

Academic medicine : journal of the Association of American Medical Colleges·2026

Related Experiment Video

Updated: Sep 8, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.3K

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.

Sujal Manohar1,2, Jennifer Jacobe1,2, Rebecca Berger1,2

  • 1Pediatric Movement Disorders Clinic, Blue Bird Circle Clinic for Pediatric Neurology, Section of Pediatric Neurology and Developmental Neuroscience, Texas Children's Hospital|Baylor College of Medicine, Houston, Texas, USA.

Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|June 23, 2025
PubMed
Summary
This summary is machine-generated.

Vesicular monoamine transporter 2 (VMAT2) inhibitors show effectiveness in treating pediatric hyperkinetic movement disorders like tics and chorea. However, access barriers, including insurance denials, hinder treatment initiation for many children.

Keywords:
VMAT2 inhibitorsdeutetrabenazinepediatric hyperkinetic movement disorderstetrabenazinevalbenazine

More Related Videos

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

6.8K
Author Spotlight: Enhancing Remote Rehabilitation with Virtual Reality and Electromyography
04:06

Author Spotlight: Enhancing Remote Rehabilitation with Virtual Reality and Electromyography

Published on: January 12, 2024

703

Related Experiment Videos

Last Updated: Sep 8, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.3K
Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

6.8K
Author Spotlight: Enhancing Remote Rehabilitation with Virtual Reality and Electromyography
04:06

Author Spotlight: Enhancing Remote Rehabilitation with Virtual Reality and Electromyography

Published on: January 12, 2024

703

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Vesicular monoamine transporter 2 (VMAT2) inhibitors are FDA-approved for adult hyperkinetic movement disorders.
  • Pediatric use is limited due to lack of specific FDA approval for children.

Purpose of the Study:

  • To review real-world prescribing practices of VMAT2 inhibitors in pediatric patients.
  • To analyze patient experiences and treatment outcomes with VMAT2 inhibitors in children.

Main Methods:

  • Retrospective chart review of pediatric patients treated with VMAT2 inhibitors.
  • Analysis of demographics, indications, medical history, and clinical notes from 2011-2023.

Main Results:

  • 340 pediatric patients received 359 VMAT2 inhibitor prescriptions, primarily for tics.
  • 62.8% of patients showed clinical improvement, but 54% faced insurance denials, impacting access.
  • Common side effects included drowsiness, with few requiring discontinuation.

Conclusions:

  • VMAT2 inhibitors demonstrate efficacy in treating pediatric hyperkinetic movement disorders.
  • Significant barriers exist in accessing these medications for pediatric patients, necessitating further investigation.